Literature DB >> 23420381

Atomoxetine-induced life-threatening long QT syndrome.

M Stuhec, V Svab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23420381     DOI： 10.1007/s11845-013-0925-y

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  12 in total

1.  Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat.

Authors:  V Russell; S Allie; T Wiggins
Journal:  Behav Brain Res       Date:  2000-12-20       Impact factor: 3.332

2.  Atomoxetine-induced electrocardiogram changes.

Authors:  A S Rajesh; G Bates; J G C Wright
Journal:  Arch Dis Child       Date:  2006-12       Impact factor: 3.791

3.  Atomoxetine-induced myocardial infarction.

Authors:  Ali Seifi; Heidi Griffith; Sahar Avestimehr; Haitham Dib
Journal:  South Med J       Date:  2011-02       Impact factor: 0.954

4.  The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD.

Authors:  J Biederman; M C Monuteaux; E Kendrick; K L Klein; S V Faraone
Journal:  Arch Dis Child       Date:  2005-10       Impact factor: 3.791

Review 5.  Long QT syndrome: reduced repolarization reserve and the genetic link.

Authors:  D M Roden
Journal:  J Intern Med       Date:  2006-01       Impact factor: 8.989

Review 6.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  J Am Coll Cardiol       Date:  2010-03-02       Impact factor: 24.094

7.  Atomoxetine changes rat's HR response to stress from tachycardia to bradycardia via alterations in autonomic function.

Authors:  Winston Y Li; Shara E Strang; David R Brown; Re'gie Smith; Dennis L Silcox; Sheng-Gang Li; Bobby R Baldridge; K Paul Nesselroade; David C Randall
Journal:  Auton Neurosci       Date:  2009-12-16       Impact factor: 3.145

Review 8.  Cardiovascular effects of atomoxetine in children, adolescents, and adults.

Authors:  Joachim F Wernicke; Douglas Faries; Donald Girod; Jeffrey Brown; Haitao Gao; Douglas Kelsey; Humberto Quintana; Robert Lipetz; David Michelson; John Heiligenstein
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents.

Authors:  Daniel Scherer; David Hassel; Ramona Bloehs; Edgar Zitron; Katharina von Löwenstern; Claudia Seyler; Dierk Thomas; Franziska Konrad; Heiner F Bürgers; Gunnar Seemann; Wolfgang Rottbauer; Hugo A Katus; Christoph A Karle; Eberhard P Scholz
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

10.  European guidelines on managing adverse effects of medication for ADHD.

Authors:  J Graham; T Banaschewski; J Buitelaar; D Coghill; M Danckaerts; R W Dittmann; M Döpfner; R Hamilton; C Hollis; M Holtmann; M Hulpke-Wette; M Lecendreux; E Rosenthal; A Rothenberger; P Santosh; J Sergeant; E Simonoff; E Sonuga-Barke; I C K Wong; A Zuddas; H-C Steinhausen; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-11-03       Impact factor: 4.785
View more
  2 in total

Review 1.  Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review.

Authors:  Shari L Hutchison; Jaswinder K Ghuman; Harinder S Ghuman; Irina Karpov; James M Schuster
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-20

Review 2.  Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.

Authors:  Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas
Journal:  Front Hum Neurosci       Date:  2022-09-26       Impact factor: 3.473
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.